Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.
about
Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas/FasL signal-independent pathway.Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.Brentuximab vedotin: clinical updates and practical guidance.
P2860
Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Brentuximab vedotin for relaps ...... ulticenter analysis from Asia.
@ast
Brentuximab vedotin for relaps ...... ulticenter analysis from Asia.
@en
Brentuximab vedotin for relaps ...... ulticenter analysis from Asia.
@nl
type
label
Brentuximab vedotin for relaps ...... ulticenter analysis from Asia.
@ast
Brentuximab vedotin for relaps ...... ulticenter analysis from Asia.
@en
Brentuximab vedotin for relaps ...... ulticenter analysis from Asia.
@nl
prefLabel
Brentuximab vedotin for relaps ...... ulticenter analysis from Asia.
@ast
Brentuximab vedotin for relaps ...... ulticenter analysis from Asia.
@en
Brentuximab vedotin for relaps ...... ulticenter analysis from Asia.
@nl
P2093
P2860
P356
P1476
Brentuximab vedotin for relaps ...... ulticenter analysis from Asia.
@en
P2093
Jung Yong Hong
Moon Ki Choi
Qing-Ming Yang
Seok Jin Kim
Shek-Ying Lin
Silvia Park
Wing-Yan Au
Won Seog Kim
Young Hyeh Ko
P2860
P304
P356
10.2147/OTT.S67380
P407
P577
2014-09-26T00:00:00Z